Editas Medicine (EDIT) CSO sells 4,928 shares for tax withholding

Rhea-AI Filing Summary

Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly sold 4,928 shares of common stock at $2.67 per share on July 28, 2026. The sale was executed under a durable Rule 10b5-1 automatic sales plan to cover tax withholding from restricted stock units vesting on July 24, 2026 and was not a discretionary trade. Following this transaction, Burkly directly held 62,369 shares of Editas Medicine common stock.

Insider Trade Summary 10b5-1

Net Seller: 4,928 shares

Net Sell 1 txn

Insider Burkly Linda

Role EVP, CHIEF SCIENTIFIC OFFICER

Sold 4,928 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	4,928	$2.67	$13K

Holdings After Transaction: Common Stock — 62,369 shares (Direct)

Footnotes (1)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Key Figures

Shares sold: 4928.0000 shares Sale price: $2.6700 per share Shares owned after sale: 62369.0000 shares +1 more

4 metrics

Shares sold 4928.0000 shares Common Stock sold on July 28, 2026

Sale price $2.6700 per share Price for the 4,928-share sale

Shares owned after sale 62369.0000 shares Direct holdings following the transaction

RSU vesting date July 24, 2026 Restricted stock units that triggered tax withholding

Key Terms

durable automatic sales instruction plan, tax withholding obligations, restricted stock units, Rule 10b5-1

4 terms

durable automatic sales instruction plan regulatory

"Sale was effected pursuant to a durable automatic sales instruction plan"

tax withholding obligations financial

"represents the sale of shares by the Issuer necessary to meet tax withholding obligations"

restricted stock units financial

"as a result of vesting in restricted stock units on July 24, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 regulatory

"document-level Rule 10b5-1 checkbox: true = transactions affirmed"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 04:51 PM Accepted by SEC EDGAR 07/29/2026 - 04:51 PM Learn about SEC filing dates

FAQ

What insider transaction did Editas Medicine (EDIT) disclose for Linda Burkly?

Editas Medicine disclosed that EVP and Chief Scientific Officer Linda Burkly sold 4,928 shares of common stock at $2.67 per share on July 28, 2026, reported as a sale in an open-market or private transaction.

Why did Linda Burkly sell shares of Editas Medicine (EDIT)?

The sale represents shares sold to meet tax withholding obligations arising from the vesting of restricted stock units on July 24, 2026. It was characterized as a transaction to cover taxes rather than a discretionary portfolio decision.

Was the Editas Medicine (EDIT) insider sale made under a Rule 10b5-1 plan?

Yes. The transaction was effected under a durable automatic sales instruction plan, affirmed as a Rule 10b5-1 trading plan and adopted on July 3, 2023, meaning the trades were pre-arranged rather than timed at the insider’s discretion.

How many Editas Medicine (EDIT) shares does Linda Burkly hold after the sale?

After selling 4,928 shares, Linda Burkly directly holds 62,369 shares of Editas Medicine common stock. This post-transaction ownership figure is reported as her direct holdings following the July 28, 2026 sale.

Does the Editas Medicine (EDIT) filing say the insider trade was discretionary?

No. The footnote states the sale “does not represent a discretionary trade” by Linda Burkly. It was executed automatically under a durable plan and tied to RSU vesting and related tax withholding needs, rather than active trading choices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burkly Linda

(Last) (First) (Middle)

11 HURLEY ST.

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF SCIENTIFIC OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		S(1)		4,928	D	$2.67	62,369	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 3, 2023, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 24, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Linda C. Burkly	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)